Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187538
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Monteil, Vanessa | - |
dc.contributor.author | Eaton, Brett | - |
dc.contributor.author | Postnikova, Elena | - |
dc.contributor.author | Murphy, Michael | - |
dc.contributor.author | Braunsfeld, Benedict | - |
dc.contributor.author | Crozier, Ian | - |
dc.contributor.author | Kricek, Franz | - |
dc.contributor.author | Niederhofer, Janine | - |
dc.contributor.author | Schwarzbock, Alice | - |
dc.contributor.author | Breid, Helene | - |
dc.contributor.author | Devignot, Stephanie | - |
dc.contributor.author | Klingstrom, Jonas | - |
dc.contributor.author | Thalin, Charlotte | - |
dc.contributor.author | Kellner, Max J | - |
dc.contributor.author | Christ, Wanda | - |
dc.contributor.author | Havervall, Sebastian | - |
dc.contributor.author | Mereiter, Stefan | - |
dc.contributor.author | Knapp, Sylvia | - |
dc.contributor.author | Sanchez Jimenez, Anna | - |
dc.contributor.author | Bugajska-Schretter, Agnes | - |
dc.contributor.author | Dohnal, Alexander | - |
dc.contributor.author | Ruf, Christine | - |
dc.contributor.author | Gugenberger, Romana | - |
dc.contributor.author | Hagelkruys, Astrid | - |
dc.contributor.author | Montserrat, Nuria | - |
dc.contributor.author | Kozieradzki, Ivona | - |
dc.contributor.author | Ali, Omar Hasan | - |
dc.contributor.author | Stadlmann, Johannes | - |
dc.contributor.author | Holbrook, Michael R | - |
dc.contributor.author | Schmaljohn, Connie | - |
dc.contributor.author | Oostenbrink, Chris | - |
dc.contributor.author | Shoemaker, Robert H | - |
dc.contributor.author | Mirazimi, Ali | - |
dc.contributor.author | Wirnsberger, Gerald | - |
dc.contributor.author | Penninger, Josef M | - |
dc.date.accessioned | 2022-07-12T08:53:56Z | - |
dc.date.available | 2022-07-12T08:53:56Z | - |
dc.date.issued | 2022-07-04 | - |
dc.identifier.citation | Monteil, Vanessa;Eaton, Brett;Postnikova, Elena;Murphy, Michael;Braunsfeld, Benedict;Crozier, Ian;Kricek, Franz;Niederhofer, Janine;Schwarzbock, Alice;Breid, Helene;Devignot, Stephanie;Klingstrom, Jonas;Thalin, Charlotte;Kellner, Max J;Christ, Wanda;Havervall, Sebastian;Mereiter, Stefan;Knapp, Sylvia;Jimenez, Anna Sanchez;Bugajska-Schretter, Agnes;Dohnal, Alexander;Ruf, Christine;Gugenberger, Romana;Hagelkruys, Astrid;Montserrat, Nuria;Kozieradzki, Ivona;Ali, Omar Hasan;Stadlmann, Johannes;Holbrook, Michael R;Schmaljohn, Connie;Oostenbrink, Chris;Shoemaker, Robert H;Mirazimi, Ali;Wirnsberger, Gerald;Penninger, Josef M. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. Embo Molecular Medicine, 2022-e15230 | - |
dc.identifier.uri | http://hdl.handle.net/2445/187538 | - |
dc.description.abstract | The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here, we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by all current VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | EMBO Press | - |
dc.relation.isformatof | https://doi.org/10.15252/emmm.202115230 | - |
dc.relation.ispartof | Embo Molecular Medicine, 2022-e15230 | - |
dc.relation.uri | https://doi.org/10.15252/emmm.202115230 | - |
dc.rights | cc by (c) Vanessa Monteil et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) | - |
dc.subject.classification | Assaigs clínics | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Vacunes | - |
dc.subject.other | Clinical trials | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Vaccines | - |
dc.title | Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants | - |
dc.type | info:eu-repo/semantics/preprint | - |
dc.date.updated | 2022-07-12T06:31:37Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 6554242 | - |
Appears in Collections: | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2022_EMBOMolMed_Clinical_MontserratN.pdf | 1.82 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License